Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb 1;97(2):E75-E78.
doi: 10.1002/ajh.26429. Epub 2021 Dec 10.

Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection

Affiliations
Clinical Trial

Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection

Filomena Longo et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

No conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
(A) Characteristics of patients with hemoglobinopathies with SARS‐CoV‐2. (B) The population histogram shows age distribution of total population (gray), age distribution of SARS‐CoV‐2 infected (blue), and lethality rate at each class (red) for Italian general population* (left) and for Italian patients with hemoglobinopathies (right). (C) The table reports pre‐existing complications significantly associated with increased severity of COVID‐19, that is, hospital admission, intensive care unit (ICU) admission, or death. Odds ratio (OR) was estimated for single comorbidity by a logistic regression analysis adjusted for age to investigate possible factors related to different risk levels. *https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino‐sorveglianza‐integrata‐COVID‐19_10‐marzo‐2021.pdf

References

    1. Bou‐Fakhredin R, Daadaa H, Koussa S, Abou Nasr T, Noun P, Taher AT. SARS‐CoV‐2 infection in patients with β‐thalassemia: experience from Lebanon. Am J Hematol. 2021;96:E285‐E288. doi:10.1002/ajh.26211 - DOI - PMC - PubMed
    1. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID‐19 infection and sickle cell disease: a UK centre experience. Br J Haematol. 2020;190:e57‐e58. - PubMed
    1. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, march 20‐may 21, 2020. Emerg Infect Dis. 2020;26:2473‐2476. - PMC - PubMed
    1. Minniti CP, Zaidi AU, Nouraie M, et al. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID‐19 infection. Blood Adv. 2021;5:207‐215. - PMC - PubMed
    1. Motta I, Migone de Amicis M, Pinto VM, et al. SARS‐CoV‐2 infection in beta thalassemia: preliminary data from the Italian experience. Am J Hematol. 2020;95:E198‐E199. - PMC - PubMed

MeSH terms